Eli Lilly's Weekly Insulin Matches Effectiveness of Daily Doses in Trials

Late-stage studies show efsitora achieves comparable blood sugar control, offering a potential shift in diabetes treatment.

Efsitora reduced A1C levels by an average of 1.34% in new insulin users over 52 weeks.
Patients on daily insulin saw a 1.26% reduction in A1C levels, showing similar efficacy.
In a 26-week trial, existing insulin users had a 1.07% drop in A1C with both weekly and daily doses.
The trials indicate efsitora's potential to reduce the treatment burden for diabetes patients.
Eli Lilly aims to compete with Novo Nordisk's upcoming weekly insulin, Awiqli.